NeuroDerm (NDRM) Given Daily News Impact Rating of 0.07

Media stories about NeuroDerm (NASDAQ:NDRM) have trended somewhat positive this week, Alpha One Sentiment reports. Alpha One, a division of Accern, ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. NeuroDerm earned a coverage optimism score of 0.07 on Alpha One’s scale. Alpha One also gave media headlines about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have effected Alpha One’s rankings:

Insider Buying and Selling by Quarter for NeuroDerm (NASDAQ:NDRM)

Shares of NeuroDerm (NDRM) remained flat at $29.10 during midday trading on Friday. 264,042 shares of the company’s stock traded hands. NeuroDerm has a 12-month low of $15.12 and a 12-month high of $30.75. The firm’s market cap is $766.44 million. The firm’s 50 day moving average price is $24.37 and its 200-day moving average price is $24.09.

NeuroDerm (NASDAQ:NDRM) last issued its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.13. Equities research analysts anticipate that NeuroDerm will post ($2.02) EPS for the current fiscal year.

A number of equities analysts recently issued reports on the company. Roth Capital set a $33.00 target price on NeuroDerm and gave the stock a “buy” rating in a report on Wednesday. Oppenheimer Holdings, Inc. upgraded NeuroDerm from a “market perform” rating to an “outperform” rating and set a $42.00 target price on the stock in a report on Wednesday. Citigroup Inc. cut NeuroDerm from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 7th. CIBC upgraded NeuroDerm from a “market perform” rating to an “outperform” rating and set a $42.00 target price on the stock in a report on Wednesday. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $42.00 target price on shares of NeuroDerm in a report on Monday, April 24th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. NeuroDerm presently has an average rating of “Buy” and a consensus target price of $43.50.

WARNING: “NeuroDerm (NDRM) Given Daily News Impact Rating of 0.07” was published by sleekmoney and is owned by of sleekmoney. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://sleekmoney.com/neuroderm-ndrm-given-daily-news-impact-rating-of-0-07/1919562.html.

NeuroDerm Company Profile

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/neuroderm-ndrm-given-daily-news-impact-rating-of-0-07/1919562.html

Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *